September 27, 2024
The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed […]
September 27, 2024
MILAN — Pregnant women with heightened amygdala activity have a reduced capacity to regulate emotions and report more symptoms of depression than those with lower activity […]
September 27, 2024
Semaglutide (Ozempic, Novo Nordisk) is associated with a significantly lower risk for overdose in individuals with opioid use disorder (OUD), new research shows. The findings suggest […]
September 27, 2024
MILAN, Italy — Tapering antipsychotic medication for patients in remission after first episode psychosis (FEP) may be challenging in the short term but beneficial over the […]
September 27, 2024
MILAN — Specific combinations of hormonal and biochemical factors were associated with different clinical characteristics and treatment outcomes of alcohol use disorder (AUD) between men and […]
September 25, 2024
TOPLINE: Treatment-resistant major depression (TRD) is associated with a 17% higher risk for all-cause mortality than non-TRD major depressive disorder (MDD), a new study shows. The […]
September 25, 2024
TOPLINE: Menopausal hormone therapy (MHT) is associated with a 16% lower risk for psychosis relapse in women with schizophrenia or schizoaffective disorder (SSD), especially in women […]
September 24, 2024
MILAN — Recent research allaying concerns about suicidality linked to glucagon-like peptide 1 (GLP-1) receptor agonists, along with evidence of these agents’ potential psychiatric and cognitive […]
September 24, 2024
Loneliness is widely recognized as a health risk factor, linked to conditions like cardiovascular disease, psychiatric disorders, and increased risks for stroke and dementia. However, new […]